FLDM - Fluidigm Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.99
-0.05 (-0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.04
Open11.03
Bid0.00 x 4000
Ask0.00 x 3100
Day's Range10.65 - 11.10
52 Week Range5.50 - 14.90
Volume1,128,982
Avg. Volume856,679
Market Cap758.529M
Beta (3Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire13 days ago

    Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report second quarter 2019 financial results on Thursday, August 1, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on August 1, 2019, to discuss second quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

  • GlobeNewswire26 days ago

    Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019

    SOUTH SAN FRANCISCO, Calif., June 20, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire27 days ago

    Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce three new Imaging Mass Cytometry™ Maxpar® panel kits and an advanced CyTOF® software solution in the third quarter to power immuno-oncology research. Imaging Mass Cytometry is rapidly advancing our understanding of health and disease by empowering researchers around the globe to deeply profile cellular phenotypes in tumors and tissues. The new ready-to-go Maxpar panel kits for immuno-oncology studies can enable researchers to rapidly profile immune infiltrates across a range of human cancer types and treatment modalities with Imaging Mass Cytometry.

  • GlobeNewswire29 days ago

    Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing the first of a series of new metal isotopes in development, these new isotopes will empower researchers to easily design and customize larger panels to advance biomarker discovery and therapeutic development. Mass cytometry is an industry-leading tool for deep interrogation of cellular phenotypes and function in health and disease.

  • GlobeNewswirelast month

    Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

    Quong will lead the company’s strategy for the generation of bold scientific insights in immunology, immuno-oncology and other frontiers of human health based on Fluidigm® technology. Quong was most recently Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research, a federally funded research and development center sponsored by the National Cancer Institute.

  • GlobeNewswire2 months ago

    Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 31, 2019, under Fluidigm’s 2017 Inducement Award Plan (“Plan”), as a material inducement to employment to an individual hired by Fluidigm in May 2019. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

  • GlobeNewswire2 months ago

    Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today introduced the Advanta™ RNA Fusions NGS Library Prep Assay for detection of over 380 gene fusion pairs from solid tumors and hematological cancers. Developed to fuel new advances in translational and clinical cancer research, the assay uniquely empowers researchers to interrogate gene fusions from a wide range of cancer types using a simple and highly efficient automated NGS library prep workflow.

  • GlobeNewswire2 months ago

    Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology

    SOUTH SAN FRANCISCO, Calif., May 29, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire2 months ago

    Fluidigm to Participate in Upcoming Health Care Investor Conferences

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York. Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York.

  • GlobeNewswire2 months ago

    Fluidigm Announces First Quarter 2019 Financial Results

    First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry.

  • GlobeNewswire2 months ago

    Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

    Fluidigm Corporation (FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging System to study regulatory T (Treg) cell proliferation in tumor tissue with the goal of discovering a novel target for immunotherapy.

  • GlobeNewswire3 months ago

    Fluidigm Announces 8th Annual Mass Cytometry Summit

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will hold the 8th Annual Fluidigm Mass Cytometry Summit on June 20 and 21, 2019, at the Pinnacle Hotel Harbourfront in Vancouver, Canada. The Summit brings together translational researchers from around the world to discuss new mass cytometry research applications and best practices for identifying biomarker signatures in health and disease and accelerating therapeutic development. “We are excited to hold this year’s Summit right before CYTO® 2019,” said Chris Linthwaite, President and CEO of Fluidigm.

  • GlobeNewswire3 months ago

    Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2019 financial results on Thursday, May 2, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on May 2, 2019, to discuss first quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

  • GlobeNewswire4 months ago

    Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting

    SOUTH SAN FRANCISCO, Calif., March 28, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through.

  • GlobeNewswire4 months ago

    Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune profiling, the system empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting. In the past two years alone, clinical trials utilizing immune cell profiling have grown by more than 30 percent, with more than 35,000 patients enrolled.

  • GlobeNewswire4 months ago

    Colin McCracken Joins Fluidigm as Chief Commercial Officer

    Fluidigm Corporation (FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, McCracken will advance Fluidigm’s commercialization infrastructure and organization toward further market adoption of the company’s products, particularly in the growing scientific community studying the human immune system.

  • GlobeNewswire5 months ago

    Fluidigm to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire5 months ago

    Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results

    Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to.

  • GlobeNewswire5 months ago

    Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and.

  • GlobeNewswire5 months ago

    Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

    Fluidigm Corporation (FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of T cell-driven immune-mediated inflammatory diseases (IMIDs). The research will potentially empower more precise treatments using existing drugs and identify new targets for future drug development.

  • GlobeNewswire5 months ago

    Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1

    SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of.

  • GlobeNewswire6 months ago

    Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.